Comparable stake leader
Innoviva, Inc.
SEC ownership of Armata Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000921114.
Disclosed value leader
Innoviva, Inc.
Comparable rows
46/50
Latest evidence
10 Jul 2026
- Public ticker
- ARMP on NYSE
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Innoviva, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
46 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Innoviva, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
10 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000921114
- Issuer location
- Los Angeles, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Armata Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Innoviva, Inc.
Disclosed value leader
Innoviva, Inc.
Comparable rows
46/50
Latest evidence
10 Jul 2026
13D/G
13F
3/4/5
Lead comparable stake: 83%
4 rows are not safely comparable across share classes.
13D/G row: Innoviva, Inc.
Showing 1-8 of 50 holder rows.
Quick read
Innoviva, Inc. leads the comparable SEC ownership view at 83%.
46 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Innoviva, Inc.'s linked filing trail.
Comparable ownership
Top 5
Innoviva, Inc.
83%
Madison Asset Management, LLC
3.1%
VANGUARD CAPITAL MANAGEMENT LLC
0.55%
MILLENNIUM MANAGEMENT LLC
0.38%
683 Capital Management, LLC
0.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Innoviva, Inc. |
13D/G
|
83%
|
$567,986,780
55,467,459 shares
|
$0 | 12 May 2026 |
| Madison Asset Management, LLC |
13F
Company
|
3.1%
|
$21,582,592
2,107,675 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
0.55%
|
$3,748,127
366,028 shares
|
— | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
0.38%
|
$2,641,838
257,992 shares
|
— | 31 Mar 2026 |
| 683 Capital Management, LLC |
13F
Company
|
0.2%
|
$1,402,880
137,000 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.17%
|
$1,173,971
114,555 shares
|
— | 31 Mar 2026 |
| EDGEWOOD MANAGEMENT LLC |
13F
Company
|
0.15%
|
$1,024,000
100,000 shares
|
— | 31 Mar 2026 |
| Dauntless Investment Group, LLC |
13F
Company
|
0.14%
|
$927,539
90,580 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 01 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Armata Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Deborah Birx
Net 12M change
$0
Latest report
10 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Deborah Birx | Chief Executive Officer, Director | $1,285,742 | Median | 10 Jul 2026 | ||
| Pierre Kyme | Chief Business Officer | $90,257 | Mixed | 14 Mar 2026 | ||
| Richard Rychlik | Corporate Controller and PFO | $50,000 | Mixed | 14 Mar 2024 | ||
| Innoviva, Inc. | Director, 10%+ Owner | Mixed | 10 Jan 2023 | |||
| Todd R. Patrick | Director | Mixed | 13 Apr 2022 | |||
| Joseph M. Patti | Director | Mixed | 09 Mar 2026 | |||
| Kostas D. Odysseas | Director | Mixed | 09 Mar 2026 | |||
| Duane Alfred Morris | VP of Operations | Mixed | 13 Apr 2022 | |||
| Brian Varnum | President and CEO | Mixed | 13 Apr 2022 | |||
| Robin Kramer | Director | Mixed | 09 Mar 2026 | |||
| Todd C. Peterson | Director | Mixed | 09 Mar 2026 | |||
| Julianne Averill | Chief Financial Officer | Mixed | 02 May 2023 | |||
| Erin Butler | Vice President,Finance & Admin | Mixed | 01 Jul 2022 | |||
| Jules Haimovitz | Director | Mixed | 09 Mar 2026 | |||
| Daniel B. Gilmer | Director | Mixed | 24 Apr 2026 | |||
| David Duane House | SVP, Finance, and PFO | Mixed | 09 Mar 2026 | |||
| Sarah J. Schlesinger | Director | Mixed | 09 Mar 2026 |
Recent insider transactions for Armata Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Deborah Birx | ARMP | Common Stock | Tax liability | -6.61% | -14,041 | 198,417 | 10 Jul 2026 | Direct | ||
| Daniel B. Gilmer | ARMP | Stock Options (Right to Buy) | Award | 51,280 | 51,280 | 24 Apr 2026 | Direct | |||
| Pierre Kyme | ARMP | Common Stock | Tax liability | -9.82% | -1,030 | 9,461 | 14 Mar 2026 | Direct | ||
| Deborah Birx | ARMP | Common Stock | Tax liability | -2.26% | -4,919 | 212,458 | 14 Mar 2026 | Direct | ||
| Robin Kramer | ARMP | Stock Options (Right to Buy) | Award | 25,640 | 25,640 | 09 Mar 2026 | Direct | |||
| Pierre Kyme | ARMP | Stock Options (Right to Buy) | Award | 183,142 | 183,142 | 09 Mar 2026 | Direct | |||
| David Duane House | ARMP | Stock Options (Right to Buy) | Award | 109,885 | 109,885 | 09 Mar 2026 | Direct | |||
| Joseph M. Patti | ARMP | Stock Options (Right to Buy) | Award | 25,640 | 25,640 | 09 Mar 2026 | Direct | |||
| Todd C. Peterson | ARMP | Stock Options (Right to Buy) | Award | 25,640 | 25,640 | 09 Mar 2026 | Direct | |||
| Kostas D. Odysseas | ARMP | Stock Options (Right to Buy) | Award | 25,640 | 25,640 | 09 Mar 2026 | Direct | |||
| Deborah Birx | ARMP | Stock Options (Right to Buy) | Award | 421,226 | 421,226 | 09 Mar 2026 | Direct | |||
| Sarah J. Schlesinger | ARMP | Stock Options (Right to Buy) | Award | 25,640 | 25,640 | 09 Mar 2026 | Direct | |||
| Jules Haimovitz | ARMP | Stock Options (Right to Buy) | Award | 25,640 | 25,640 | 09 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.